Ardelyx (NASDAQ:ARDX) will host a conference call tomorrow, December 3, at 8:00 am ET to discuss results from the Phase 3 PHREEDOM study evaluating tenapanor in chronic kidney disease patients on dialysis.
In September, the company announced that the trial met the primary and all key secondary endpoints.
Shares up 1% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.